Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 2/20 | 0.43 |
| ▸ | MMP2 | P08253 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 2/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | MMP8 | P22894 | 2/20 | 0.39 |
| ▸ | MMP13 | P45452 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL140930 | 0.88 | MMP2 (0.47) | STAT3MMP2CA12CA9CA14 | |
| SCHEMBL5134686 | 0.86 | ENPP2 (0.42) | KMT2A | |
| SCHEMBL23703227 | 0.86 | GAA (0.43) | STAT3CA12CA9GAAKMT2A | |
| SCHEMBL14390991 | 0.83 | STAT3 (0.42) | STAT3MMP2CA12CA9CA14 | |
| Butane SCHEMBL15941687 | 0.83 | MMP2 (0.44) | STAT3MMP2CA12CA9CA14 | |
| SCHEMBL4206461 | 0.81 | STAT3 (0.40) | STAT3MMP2CA12CA9CA14 | |
| SCHEMBL140173 | 0.81 | GAA (0.42) | STAT3CA12CA9GAAKMT2A | |
| SCHEMBL13010448 | 0.80 | ALDH1A1 (0.40) | STAT3CA12CA9GAAKMT2A | |
| SCHEMBL8622516 | 0.80 | MMP2 (0.41) | STAT3MMP2CA12CA9CA14 | |
| SCHEMBL8871679 | 0.79 | STAT3 (0.43) | STAT3CA12CA9GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170029451-A1 | BRANCHED CHAIN ACYCLIC NUCLEOSIDE PHOSPHONATE ESTERS AND METHODS OF SYNTHESIS AND USES THEREOF | CHIMERIX, INC. | 2017-02-02 | — | — | US | disclosed |
| US-20120058976-A1 | Phosphonate Ester Derivatives and Methods of Synthesis Thereof | CHIMERIX, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20100081634-A1 | Novel Phosphorus-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-7514419-B2 | Phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| EP-1891080-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | Metabasis Therapeutics, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1890768-A2 | NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS | Metabasis Therapeutics, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006128056-A2 | NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006128055-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081634-A1 | Novel Phosphorus-Containing Thyromimetics | PYGL, THRA, THOP1 | STAT3 914/4885MMP2 1839/4885CA12 1252/4885 |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | PYGL, THRA, THOP1 | STAT3 914/4885MMP2 1839/4885CA12 1252/4885 |
| US-20170029451-A1 | BRANCHED CHAIN ACYCLIC NUCLEOSIDE PHOSPHONATE ESTERS AND METHODS OF SYNTHESIS AND USES THEREOF | POLN, PC, TYMP | STAT3 3410/4885MMP2 3581/4885CA12 1337/4885 |
| US-20120058976-A1 | Phosphonate Ester Derivatives and Methods of Synthesis Thereof | PHOSPHO1, PIK3CA, PNP | STAT3 3774/4885MMP2 3084/4885CA12 1841/4885 |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | PYGL, PHOSPHO1, LIPE | STAT3 1029/4885MMP2 2143/4885CA12 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.